The global fight against polio received a significant boost this month with the World Health Organization’s (WHO) prequalification of an additional novel oral polio vaccine type 2 (nOPV2). This expanded access to a critical tool for controlling outbreaks, particularly in regions with low immunization rates, and reinforces international efforts toward polio eradication. The prequalification, announced February 13, 2026, signifies the vaccine meets rigorous international standards for quality, safety, and efficacy.
Poliomyelitis, a highly infectious viral disease, primarily affects young children and can lead to irreversible paralysis. While wild poliovirus has been eliminated from most of the world, the emergence of circulating vaccine-derived poliovirus type 2 (cVDPV2) continues to pose a challenge, particularly in areas with insufficient vaccination coverage. The nOPV2 vaccine is designed to address these outbreaks, offering a more stable alternative to traditional oral polio vaccines.
What WHO Prequalification Means for Global Health
WHO prequalification is a crucial step in ensuring vaccines are safe and effective for global immunization programs. It confirms that the nOPV2 vaccine meets stringent international standards, allowing procurement through United Nations agencies like UNICEF. This streamlined process facilitates wider distribution to countries actively responding to polio outbreaks and provides confidence to national immunization programs operating in challenging environments. The process also ensures quality control and consistent manufacturing standards.
Expanding the Supply Chain: India and Indonesia Collaboration
The newly prequalified vaccine is manufactured by Biological E. Limited (BioE) in India, utilizing bulk vaccine produced through a technology transfer from PT Bio Farma in Indonesia. This diversification of the manufacturing base is a strategic move to bolster the resilience and reliability of the global nOPV2 supply chain, ensuring a consistent stockpile during outbreak responses. Previously, WHO had listed nOPV2 manufactured by PT Bio Farma, as well as the vaccine formulated and filled by BioE using bulk supplied by the Indonesian company, demonstrating a growing network of qualified producers.
Why nOPV2 Represents a Step Forward in Polio Control
The nOPV2 vaccine is engineered to be more genetically stable than the traditional monovalent oral polio vaccine type 2. This key difference significantly reduces the risk of the vaccine itself triggering new outbreaks, a concern with earlier formulations. Despite this enhanced stability, nOPV2 retains its effectiveness in rapidly interrupting poliovirus transmission. Since its initial deployment, the vaccine has been used in numerous emergency responses, reaching hundreds of millions of children worldwide, according to WHO data. As of November 2024, approximately 1.3 billion doses of nOPV2 had been administered in 41 countries during nearly 250 outbreak response campaigns.
Real-World Impact and Ongoing Surveillance
The impact of vaccination campaigns, including those utilizing nOPV2, was highlighted by the WHO Director-General at a recent Executive Board meeting, noting a decline in the number of wild poliovirus cases globally. The nOPV2 vaccine is authorized for emergency use across all age groups when deemed necessary by the WHO or the Global Polio Eradication Initiative, enabling swift containment of outbreaks. A subcommittee of the Global Advisory Committee on Vaccine Safety (GACVS) reviewed safety data from over 1 billion administered doses of nOPV2 between March 2021 and December 2023, finding no evidence of unexpected safety concerns or adverse event clusters.
Still, the WHO emphasizes that sustained surveillance, adequate financing, and continued political commitment remain essential to achieving a polio-free world. The organization recommends continued strong surveillance and reporting of adverse events following immunization (AEFIs), including cVDPV2 emergencies. Findings from the safety monitoring of nOPV2 during the Emergency Use Listing period will be reported to the Strategic Advisory Group of Experts on Immunization (SAGE).
The prequalification of this additional nOPV2 vaccine is a testament to collaborative efforts in global health and a crucial step toward protecting vulnerable populations from the devastating effects of polio. The WHO continues to diversify and strengthen the manufacturing base for quality-assured nOPV2, helping to ensure a more resilient, reliable and sustainable vaccine supply for countries responding to outbreaks.
Disclaimer: This article provides information about a public health topic and is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The WHO will continue to monitor the safety and effectiveness of nOPV2 and provide updates as new data become available. The next major checkpoint will be the presentation of findings from the ongoing safety monitoring to the Strategic Advisory Group of Experts on Immunization (SAGE).
Share this article to help raise awareness about the ongoing efforts to eradicate polio and protect children worldwide.
